Image

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants

Randomized Controlled Crossover Trial of Postpyloric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants

Recruiting
1 years and younger
All
Phase N/A

Powered by AI

Overview

The purpose of this study is to determine if postpyloric feedings effectively improve objective measures of pulmonary health in preterm infants with chronic lung disease when compared with nasogastric (NG) feedings. This research will (1) determine the optimal nutritional management to prevent a common and costly complication of prematurity, and (2) use a novel crossover design that examines outcomes of clinical endpoints alongside biomarkers.

Description

Bronchopulmonary dysplasia (BPD) affects up to 50,000 preterm infants annually in the United States and is the most common complication of prematurity. Despite improving survival in preterm infants, incidence of BPD is increasing. Overall, 11% of infants are born preterm in the United States annually. While many outcomes of prematurity, including survival, have improved over time, the incidence of BPD has increased.

Nearly all babies with BPD require provision of feeds via an enteral tube due to feeding immaturity and ongoing need for respiratory support, and up to ΒΌ of babies with the most severe forms of BPD require this long-term, and are discharged home with nasal or surgically placed feeding tubes. However, enteral feeding into the stomach frequently results in reflux in preterm infants. This may cause aspiration into the respiratory tract, which can result in further damage to the lungs and worsen respiratory outcomes.

The study will measure the impact of NJ feedings on lung disease severity in a prospective crossover trial among infants at high-risk of developing BPD.

Each randomized patient will participate in two blocks of feeding, a nasogastric (NG) and a nasojejunal (NJ, postpyloric) block. Subjects will be randomized to either the control (NG) or intervention (NJ) feedings in the first block. Outcomes will be compared pairwise by subject between the NG and NJ blocks.

The findings of this study would be immediately impactful for neonatologists, pediatricians, pediatric pulmonologists, pediatric gastroenterologists, advanced practitioners, and nutritionists who determine nutritional strategies for preterm infants.

Eligibility

Inclusion Criteria:

        Preterm infants born < 32 weeks' gestation may enroll at 34-44 weeks post-menstrual age,
        who:
          1. Remain on either invasive ventilation or non-invasive ventilation (continuous positive
             airway pressure or nasal intermittent positive pressure ventilation) for minimum 48
             hours at the time of study entry. The minimum support required for inclusion is CPAP >
             5cm H2O or CPAP 5 with FiO2 > 21%.
          2. Have ongoing need for respiratory support due to underlying lung disease from
             prematurity.
          3. Are tolerating > 80 ml/kg/day of enteral feedings at baseline, either via nasogastric
             (NG) or nasojejunal (NJ) tube. Patients may be receiving gastric (NG) or postpyloric
             (NJ) feedings.
        Exclusion Criteria:
          1. Infants who are transiently on respiratory support at the time of study entry due to
             another reason than underlying lung disease from prematurity; for example, recovery
             from a surgical intervention.
          2. Infants who have other comorbidities that significantly contribute to lung disease,
             including cyanotic congenital heart disease, or other genetic, congenital, or
             pulmonary abnormalities.
          3. Infants who were evaluated for necrotizing enterocolitis (including holding feedings)
             in the 7 days prior to study enrollment.
          4. Infants with known gastrointestinal or airway malformations that would affect
             tolerance of feeds or the route of delivery of enteral feedings.

Study details
    Bronchopulmonary Dysplasia

NCT05777512

Boston Children's Hospital

27 January 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.